希罗达联合新辅助化疗治疗老年晚期耐药乳腺癌的临床价值

Clinical value of Xeloda combined with neoadjuvant chemotherapy in the treatment of elderly with drug resistance breast cancer

目的 观察希罗达联合新辅助化疗对老年晚期耐药乳腺癌的疗效及毒性反应.方法 收集2010年10月～2011年10月衡水市第二人民医院乳腺癌术后复发或转移的老年女性患者84例,将其随机分为对照组和观察组,各42例,对照组给予新辅助化疗方案,即蒽环类联合多西紫杉醇,观察组在对照组的基础上,给予希罗达化疗.周期完成后3周行疗效评估.结果 对照组有效率为30.9％,临床收益率为71.4％;观察组有效率为83.3％,临床收益率为92.9％,两者有效率及临床收益率比较,差异均有统计学意义（x2=10.910、10.200,均P＜0.05）.两组主要毒性反应为手足综合征、骨髓抑制、恶心呕吐、腹泻食差、谷丙转氨酶升高、谷草转氨酶升高,两组在上述方面比较,差异均有统计学意义（x2=14.357、12.384、10.887、14.035、12.006、15.612,均p＜0.05）.结论 希罗达联合新辅助化疗治疗老年晚期耐药乳腺癌疗效确切,耐受性好,口服方便,是一较好的靶向性药物.

Objective To evaluate the efficacy and toxicity of Xeloda combined with neoadjuvant chemotherapy in the treatment of elderly with drug resistance breast cancer.Methods 84 women patients with elderly of breast cancer recurrence or metastasis from October 2010 to October 2011 in the Second People＇s Hospital of Hengshui City were collected,and randomly divided into control group and observation group,with 42 cases in each group respectively,and the control group was given the new adjuvant chemotherapy scheme,namely anthracycline-based combined with Docetaxel,observation group on the basis of the control group was given Xeloda,curative effect was evaluated after the completion of chemotherapy cycle for 3 weeks.Results Effective rate of the control group was 30.9％,clinical yield was 71.4％.Effective rate of observation group was 83.3％,clinical yield was 92.9％,the differences of the clinical efficiency and yield for comparison were statistically significant （X2=10.910,10.200,all P ＜ 0.05）.The differences of two groups of major toxic effects to extremities syndrome,bone marrow suppression,nausea,vomiting,diarrhea,poor food and elevated ALT,AST,rise for comparison were statistically significant （x2=14.357,12.384,10.887,14.035,12.006,15.612,all P ＜ 0.05）.Conclution Xeloda combined with neoadjuvant chemotherapy in the treatment of elderly with drug resistance breast cancer is efficacy,tolerability,and convenient by oral,it is reserved as a better targeted medicine.